News >

Studies Add to Evidence of Utility of Blood-Based Biomarkers in NSCLC

Wayne Kuznar
Published: Monday, Oct 07, 2019

Dr Shirish Gadgeel

Shirish Gadgeel, MD

Evidence is increasing that blood-based biomarkers have predictive utility in advanced non–small cell lung cancer (NSCLC). Going further, blood-based next-generation sequencing (NGS) appears to have clinical utility in selecting targeted treatment in this setting. The performance of blood-based biomarkers in the setting of advanced NSCLC was the subject of several presentations at the 2019 ESMO Congress, 2 of which are summarized here.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Burst CME™ – Cancer Summaries and Commentaries: Update from Toronto: Advances in the Treatment of Lung CancersNov 30, 20190.5
Publication Bottom Border
Border Publication
x